Corona Remedies made a strong debut on the stock exchanges on December 11, 2025, after witnessing significant demand during its initial public offering. The company’s shares were listed at ₹1,470 on the National Stock Exchange (NSE), representing a premium of 38.42 percent over the issue price. On the Bombay Stock Exchange (BSE), the stock opened at ₹1,452, marking a premium of 36.72 percent.
Listing Performance
The listing prices were well above the upper end of the IPO price band of ₹1,062 per share. Following the market debut, Corona Remedies’ market capitalisation stood at approximately ₹8,880.44 crore. The strong premium on listing reflected high investor participation during the offering.
IPO Overview
The ₹655.37 crore IPO was open for subscription from December 8 to December 10 and was subscribed 137.04 times. The public issue consisted entirely of an offer for sale (OFS) of 61.71 lakh equity shares by promoters and existing shareholders. As the IPO was structured as an OFS, the company did not receive any proceeds from the issue.
Selling shareholders included Sepia Investments, Anchor Partners, and Sage Investment Trust. The price band for the issue was fixed at ₹1,008 to ₹1,062 per share. JM Financial, IIFL Capital, and Kotak Capital acted as the book-running lead managers, while Bigshare Services served as the registrar to the issue.
Company Profile and Operations
Corona Remedies is a pharmaceutical company focused on branded formulations in the Indian market. Its product portfolio spans multiple therapeutic segments, including women’s healthcare, cardio-diabeto, pain management, and urology.
According to data from CRISIL Intelligence, the company ranked as the second fastest-growing player among the top 30 companies in the Indian Pharmaceutical Market between MAT June 2022 and MAT June 2025. During this period, Corona Remedies recorded a compound annual growth rate of 16.77 percent in domestic sales, compared with an industry growth rate of 9.21 percent.
Market Response
The strong listing followed exceptional demand in the primary market, with investors showing interest across categories. The debut has placed Corona Remedies among notable pharmaceutical listings in recent years, supported by its growth trajectory and presence across key therapeutic areas.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.